Aura Biosciences (AURA) announced that additional Phase 1 data evaluating bel-sar for the treatment of patients with non-muscle invasive bladder cancer will be presented at the 40th Annual European Association of Urology Congress being held March 21-24, 2025, in Madrid, Spain. Aura will also participate in the EAU Research Forum during the Congress.
Education
About Us
Working with TipRanks
Follow Us
1